108132-05-4

Basic information

• Product Name: 1-(4-HYDROXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE
• Synonyms: 1-(4-HYDROXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE;trans-4'-Hydroxy-3,4,5-trimethoxychalcone
• CAS NO: 108132-05-4
• Molecular Formula: C₁₈H₁₈O₅
• Molecular Weight: 314.33
• Mol File: 108132-05-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 156 °C(Solv: ethanol (64-17-5))
• Boiling Point: 511.1°C at 760 mmHg
• Flash Point: 185.5°C
• Appearance: /
• Density: 1.207g/cm³
• Vapor Pressure: 4.55E-11mmHg at 25°C
• Refractive Index: 1.599
• PKA: 7.56±0.15(Predicted)
• CAS DataBase Reference: 1-(4-HYDROXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-HYDROXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(108132-05-4)
• EPA Substance Registry System: 1-(4-HYDROXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(108132-05-4)

Safety Data

• Hazardous Substances Data: 108132-05-4(Hazardous Substances Data)

Usage

General Description

1-(4-HYDROXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE is a chemical compound with a molecular structure containing a prop-2-en-1-one group and two phenyl groups, one of which is hydroxylated and the other is substituted with three methoxy groups. 1-(4-HYDROXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE has potential applications in pharmaceuticals and organic synthesis due to its unique structure and properties. It may possess antioxidant, anti-inflammatory, or other biological activities, making it potentially valuable in drug development or as a research tool in the field of molecular biology. However, further research is needed to fully understand its characteristics and potential applications.

InChI:InChI=1/C18H18O5/c1-21-16-10-12(11-17(22-2)18(16)23-3)4-9-15(20)13-5-7-14(19)8-6-13/h4-11,19H,1-3H3/b9-4+

Upstream product

• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 99-93-4 4-Hydroxyacetophenone 

Downstream Products

• 1214751-13-9 [3-(4-hydroxyphenyl)-5-(3,4,5-trimethoxyphenyl)-4,5-dihydropyrazol-1-yl]pyridin-3-yl-methanone 
• 1603988-64-2 2-(4-(3-(3,4,5-trimethoxyphenyl)isoxazol-5-yl)phenoxy)acetic acid 
• 1603988-43-7 C₁₈H₁₇NO₅ 
• 1360872-62-3 C₂₁H₂₀O₅ 
• 1360872-64-5 C₅₃H₅₀N₆O₁₁ 
• 1360872-60-1 C₄₆H₄₄N₈O₁₀S 

Relevant articles and documents

A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe

In current work, a class of novel 4,5-dihydro-1H-pyrazole-1-carboxylate derivatives (E01-E28) were designed, synthesized and evaluated. Among them, the most potent compound E24 exhibited comparable activity against a panel of cancer cells (GI50

Synthesis of some novel substituted phenylisoxazol phenoxy 2-methylpropanoic acids and there in vivo hypolipidemic activity

The novel series of phenylisoxazol phenoxy 2-methylpropanoic acid derivatives were synthesized and evaluated for their in vivo hypolipidemic activity by triton WR-1339-induced hyperlipidemia in rats. The newly synthesized compounds 5a and 5i showed significant decrease in the serum TCH, TG, LDL and VLDL along with an increase in serum HDL levels as compared to standard drug Fenofibrate. The treated groups also showed significant decrease in the atherogenic index, TC:HDL risk ratios compared to cholesterol-induced hyperlipidemic control group. These molecules indeed have the potential to be developed as antihypolipidemic molecules.

Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents

Chalcones have been identified as interesting compounds with cytotoxicity, anti-inflammatory and antioxidant properties. In the present study, simple methoxychalcones were synthesized by Claisen-Schmidt condensation reaction and evaluated for above biological activities. The structures of the compounds were established by IR, 1H NMR and mass spectral analysis. The data revealed that compound 3s (99-100% at 10 μM concentration) completely inhibit the selected five human cancer cell lines as compared to standard flavopiridol and gemcitabine (70-90% at 700 nM and 500 nM concentrations, respectively), followed by 3a, 3n, 3o, 3p, 3q, 3r. Among the tested compounds 3l, 3m, 3r, and 3s exhibited promising anti-inflammatory activity against TNF-α and IL-6 with 90-100% inhibition at 10 μM concentration. DPPH free radical scavenging activity was given by the compounds 3o, 3n, 3l, 3r, 3m, 3a, 3p, 3c and 3s at 1 mM concentration. Overall, 3s was obtained as lead compound with promising anticancer, anti-inflammatory and antioxidant activities. Bioavailability of compounds were checked by in vitro cytotoxicity study and confirmed to be nontoxic. The structure activity relationship (SAR) and in silico drug relevant properties (HBDs, HBAs, PSA, c Log P, ionization potential, molecular weight, EHOMO and ELUMO) further confirmed that the compounds were potential candidates for future drug discovery study.